-
October 26, 2022Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Elpiscience announced it will have five poster presentations at the SITC 2022 Annual Meeting.
-
May 09, 2022Elpiscience Announces FDA IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
ES014 is a first in class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways.
-
May 06, 2022Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers
ES104 in combination with paclitaxel showed a high ORR including responses in all four BTC subtypes and good overall tolerability consistent with prior studies.
-
February 28, 2022Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104 for Treatment of Colorectal Cancer
ES104 is currently the only clinical-stage bispecific antibody targeting VEGF and DLL4 in China.
-
February 11, 2022Elpiscience to Participate in Cross-Pacific Collaboration Panel at BIO CEO & Investor Conference
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, toda...
-
February 09, 2022Elpiscience Announces CDE Clearance of IND Application for Anti-CD39 Monoclonal Antibody ES002
Elpiscience Biopharmaceuticals announced that the Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES002 to initiate a Phase I clinic